117 related articles for article (PubMed ID: 20576295)
1. A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas.
Balhorn RL; Skorupski KA; Hok S; Balhorn MC; Guerrero T; Rebhun RB
Vet Immunol Immunopathol; 2010 Oct; 137(3-4):235-42. PubMed ID: 20576295
[TBL] [Abstract][Full Text] [Related]
2. Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia.
Balhorn R; Hok S; Burke PA; Lightstone FC; Cosman M; Zemla A; Mirick G; Perkins J; Natarajan A; Corzett M; DeNardo SJ; Albrecht H; Gregg JP; DeNardo GL
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5621s-5628s. PubMed ID: 17875798
[TBL] [Abstract][Full Text] [Related]
3. Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells.
West J; Perkins J; Hok S; Balhorn R; Lightstone FC; Cosman M; DeNardo SJ; DeNardo GL
Cancer Biother Radiopharm; 2006 Dec; 21(6):645-54. PubMed ID: 17257080
[TBL] [Abstract][Full Text] [Related]
4. Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules.
Albrecht H; Cosman M; Ngu-Schwemlein M; Corzett M; Curran KW; Dolan C; Fang X; DeNardo SJ; DeNardo GL; Balhorn R
Cancer Biother Radiopharm; 2007 Aug; 22(4):531-42. PubMed ID: 17803448
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia.
Hok S; Natarajan A; Balhorn R; DeNardo SJ; DeNardo GL; Perkins J
Bioconjug Chem; 2007; 18(3):912-21. PubMed ID: 17373772
[TBL] [Abstract][Full Text] [Related]
6. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma.
Jubala CM; Wojcieszyn JW; Valli VE; Getzy DM; Fosmire SP; Coffey D; Bellgrau D; Modiano JF
Vet Pathol; 2005 Jul; 42(4):468-76. PubMed ID: 16006606
[TBL] [Abstract][Full Text] [Related]
7. Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging.
DeNardo GL; Natarajan A; Hok S; Mirick G; DeNardo SJ; Corzett M; Sysko V; Lehmann J; Beckett L; Balhorn R
Cancer Biother Radiopharm; 2008 Dec; 23(6):783-96. PubMed ID: 20443696
[TBL] [Abstract][Full Text] [Related]
8. Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors.
Zhang N; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2007 Jun; 22(3):342-56. PubMed ID: 17651040
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma.
DeNardo GL; Hok S; Van Natarajan A; Cosman M; DeNardo SJ; Lightstone FC; Mirick GR; Yuan A; Perkins J; Sysko VV; Lehmann J; Balhorn RL
Int J Oncol; 2007 Oct; 31(4):729-40. PubMed ID: 17786303
[TBL] [Abstract][Full Text] [Related]
10. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential.
Epstein AL; Marder RJ; Winter JN; Stathopoulos E; Chen FM; Parker JW; Taylor CR
Cancer Res; 1987 Feb; 47(3):830-40. PubMed ID: 3542194
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
12. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10.
Rose LM; Gunasekera AH; DeNardo SJ; DeNardo GL; Meares CF
Cancer Immunol Immunother; 1996 Sep; 43(1):26-30. PubMed ID: 8917632
[TBL] [Abstract][Full Text] [Related]
13. Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors.
Biddle WC; Pancook J; Goldrosen M; Han T; Foon KA; Vaickus L
Cancer Res; 1990 May; 50(10):2991-6. PubMed ID: 2334902
[TBL] [Abstract][Full Text] [Related]
14. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
15. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
16. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation.
Impellizeri JA; Howell K; McKeever KP; Crow SE
Vet J; 2006 May; 171(3):556-8. PubMed ID: 16624725
[TBL] [Abstract][Full Text] [Related]
17. Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study.
Ruco LP; Pomponi D; Pigott R; Stoppacciaro A; Monardo F; Uccini S; Boraschi D; Tagliabue A; Santoni A; Dejana E
Am J Pathol; 1990 Nov; 137(5):1163-71. PubMed ID: 1700619
[TBL] [Abstract][Full Text] [Related]
18. DNA ploidy and cell kinetic characteristics in canine non-Hodgkin's lymphoma.
Teske E; Rutteman GR; Kuipers-Dijkshoorn NJ; van Dierendonck JH; van Heerde P; Cornelisse CJ
Exp Hematol; 1993 Apr; 21(4):579-84. PubMed ID: 8462667
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma.
DeNardo GL; Natarajan A; Hok S; Perkins J; Cosman M; DeNardo SJ; Lightstone FC; Mirick GR; Miers LA; Balhorn RL
J Nucl Med; 2007 Aug; 48(8):1338-47. PubMed ID: 17631545
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma.
Fosmire SP; Thomas R; Jubala CM; Wojcieszyn JW; Valli VE; Getzy DM; Smith TL; Gardner LA; Ritt MG; Bell JS; Freeman KP; Greenfield BE; Lana SE; Kisseberth WC; Helfand SC; Cutter GR; Breen M; Modiano JF
Vet Pathol; 2007 Jul; 44(4):467-78. PubMed ID: 17606508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
